Tarsus Pharmaceuticals, Inc. (TARS)

NASDAQ • Healthcare

$73

-$2.45 (-3.3%)

Market closed

Last close at October 2, 2026 at 20:00 UTC

Open$75.84

Day Range$72.94 - $75.84

Avg. Volume (3M)798.8K

Market Cap$3.1B

52 Week Range

$53.89$91.53

Next EarningsIn 30 daysNov 3, 2026

Metrics Over Time

Where the Money Goes

Q2 2026

Revenueeverything earned$173.9M100%

Gross Profitminus cost of goods$161.7M93%

In plain terms: out of every $100 in revenue, Tarsus Pharmaceuticals, Inc. currently loses $11.

Fundamentals & Financials

Revenue (TTM)

$606.3M

Net Income (TTM)

-$46.4M

EPS (TTM)

-$1.09

ROA (TTM)

-7.6%

Current Ratio

3.2

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Income Statement

Balance Sheet

Financial Highlights

Dividends History

Split History

Earnings

-45.5%Q3 2025-$0.48

+14.3%Q4 2025-$0.3

-94.2%Q1 2026-$0.2

+60.2%Q2 2026-$0.16

-124.2%Q3 2026-$0.43

Nov 3

in 30 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Next report — what to expect

Tarsus Pharmaceuticals, Inc. (TARS) reports on November 3, 2026. Wall Street’s next-period consensus calls for EPS of -$1.49 on revenue of $182.7 million. For trailing context, revenue rose +69.4% year over year last quarter. The company has beaten EPS in 5 of 8 most recent quarters.

View full earnings history

About Tarsus Pharmaceuticals, Inc.

Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) is a biotechnology company developing lotilaner-based medicines, centered mainly on ocular disease while extending into dermatology and infectious-disease uses. In FY2025, it recorded $451.4 million in revenue. Its work is organized around investigational therapies for blepharitis, rosacea, Lyme disease prevention, and community-level malaria reduction.

Name

Tarsus Pharmaceuticals, Inc.

CEO

Bobak R. Azamian

Website

www.tarsusrx.com

Industry

Healthcare

Year Founded

2016

Employees

370

Today's Snapshot

AI-generated

TARS closed 3.3% below yesterday's close, while its sector was flat.

Trading Volume

Below 10d avg (816.5K)

633.1K

vs S&P 500 Today

Strong Underperformance

-4.04%

Updated: October 2, 2026 at 20:15 UTC

Technical Indicators

2 Buy3 Neutral3 Sell

TARS shows a sell bias with mixed time-frame signals and subdued trend strength. The stock trades around 73, below short-term averages in the mid 70s yet still above several medium and long-term moving averages, creating a conflicted structure, while ADX near 21 indicates only modest trend conviction. Momentum measures are negative and CCI is oversold, even as MACD is neutral and RSI remains below midpoint. ATR is moderate and OBV points to distribution, while pivot resistance around 76.5 aligns with recent weakness. Technical takeaway: Sell.

All signals